A5077320383- Angiogenesis and VEGF in Cancer
- Lymphatic System and Diseases
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Mast cells and histamine
- RNA Research and Splicing
- Diverse Scientific Research Studies
- Immune cells in cancer
- Sarcoidosis and Beryllium Toxicity Research
- Monoclonal and Polyclonal Antibodies Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- T-cell and B-cell Immunology
- Systemic Sclerosis and Related Diseases
- RNA and protein synthesis mechanisms
- Viral Infections and Immunology Research
- Myasthenia Gravis and Thymoma
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
aTyr Pharma (United States)
2020-2025
Although blocking the binding of vascular endothelial growth factor (VEGF) to neuropilin-2 (NRP2) on tumor cells is a potential strategy treat aggressive carcinomas, lack effective reagents that can be used clinically has hampered this therapy. Here, we describe generation fully humanized, high-affinity monoclonal antibody (aNRP2-10) specifically inhibits VEGF NRP2, conferring antitumor activity without causing toxicity. Using triple-negative breast cancer as model, demonstrated aNRP2-10...
Interstitial lung disease (ILD) consists of a group immune-mediated disorders that can cause inflammation and progressive fibrosis the lungs, representing an area unmet medical need given lack disease-modifying therapies toxicities associated with current treatment options. Tissue-specific splice variants (SVs) human aminoacyl-tRNA synthetases (aaRSs) are catalytic nulls thought to confer regulatory functions. One example from histidyl-tRNA synthetase (HARS), termed HARS WHEP because...
Neuropilin-2 (NRP2) is a cell surface receptor that plays key roles in lymphangiogenesis, but also pathophysiological conditions such as cancer and inflammation. NRP2 targeting by efzofitimod, novel immunomodulatory molecule, currently being tested for the treatment of pulmonary sarcoidosis. To date, no anti-NRP2 antibodies are available companion diagnostics. Here we describe development characterization antibody. Using variety research techniques, is, enzyme-linked immunoassay, Western...
The autoimmune disease known as Jo-1 positive anti-synthetase syndrome (ASS) is characterized by circulating antibody titers to histidyl-tRNA synthetase (HARS), which may play a role in modulating the non-canonical functions of HARS. Monoclonal antibodies HARS were isolated single-cell screening and sequencing from three ASS patients shown be high affinity, covering diverse epitope space. immune response was further repertoire most productive donor samples. In line with previous studies...
<h3>Background</h3> Neuropilin-2 (NRP2) is a single transmembrane pleiotropic receptor that utilizes co-receptors for signal transduction and known to impact tumor progression metastasis.<sup>1</sup> Deletion of NRP2 in murine tumor-associated macrophages (TAMs) downregulated several immunosuppressive tumor-promoting genes upregulated immune-stimulatory the myeloid compartment.<sup>2</sup> However, little about role human TAMs. We previously reported significant expression on TAMs derived...
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is an autoimmune characterized by inflammation and fibrosis of skin lungs. Efzofitimod immunomodulator that has demonstrated clinical proof-of-concept (POC) in pulmonary sarcoidosis, a related ILD. In animal models ILD, including SSc-ILD, efzofitimod reduced fibrosis. binds to neuropilin-2 (NRP2), membrane protein upregulated at sites inflammation, most notably on myeloid cells which are involved the pathology both sarcoidosis...